Coronavirus: EMA approves additional manufacturing capacity for Pfizer/BioNTech COVID-19 vaccine

date: 02/06/2021

The European Medicines Agency (EMA) has recommended the approval of additional manufacturing and filling lines at Pfizer’s vaccine manufacturing site in Puurs, Belgium.

Based on the review of the data submitted by BioNTech Manufacturing GmbH, EMA’s decision reaffirms that the Puurs manufacturing site is capable of consistently producing high-quality vaccines and enables Pfizer/BioNTech to increase the volumes of vaccines produced at this site.

The recommendation by the Committee for Medicinal Products for Human Use (CHMP) is expected to have a significant and immediate impact on European supplies of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.

Last updated on 02/06/2021